Clinical Trial Update: Safety and Efficacy Study of PB127 Ultrasound Contrast Agent for Diagnosis of Coronary Artery Disease [Phase 3]

View source ↗

Summary

A Phase 3 safety and efficacy trial of PB127 ultrasound contrast agent for diagnosing coronary artery disease has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Artery Disease

Drugs mentioned

• PB127 Ultrasound Contrast Agent

Snippet

Sponsor: Point Biomedical | Conditions: Coronary Artery Disease | Phase 3 | Status: TERMINATED